Global Cardiac Biomarkers Testing Market Size and Forecast to 2029: Revenue, Growth, and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the cardiac biomarkers testing market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Cardiac Biomarkers Testing Market Size Today And What Will Its Value Be At The End Of 2029?

The cardiac biomarkers testing market size has experienced rapid growth in recent years. It is projected to increase from $13.48 billion in 2024 to $14.95 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.9%. The expansion observed in the historic period is attributable to the rising incidence of cardiovascular diseases, an aging global population, various awareness and education initiatives, supportive government initiatives and healthcare policies, and increasing healthcare expenditure.

The cardiac biomarkers testing market is projected to experience substantial expansion in the coming years. It is anticipated to reach a value of $23.24 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.7%. This projected growth during the forecast period can be ascribed to factors such as personalized medicine, the escalating worldwide prevalence of cardiovascular diseases, the incorporation of artificial intelligence (AI) into diagnostic processes, the spread of point-of-care testing, and a growing focus on the early identification of diseases. Key trends expected during this period encompass technological progress, improvements in AI-assisted diagnostics, the expansion of point-of-care testing (POCT), enhanced multiplexing capabilities, and ongoing biomarker discovery and validation efforts.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

Which Key Drivers Are Powering Growth In The Cardiac Biomarkers Testing Market?

The expanding occurrence of cardiovascular diseases is anticipated to invigorate the growth of the cardiac biomarkers testing market in the coming years. Cardiovascular disease describes conditions affecting the heart or blood vessels. Cardiac biomarker tests are instrumental in assessing biomarker levels to quickly ascertain the severity and extent of a heart attack. Thus, a rise in cardiovascular disease prevalence will consequently increase the demand for cardiac biomarker testing solutions. For example, in August 2022, the American College of Cardiology, a US-based professional medical organization, projected a significant escalation in cardiovascular risk factors and disease rates within the United States by the year 2060. Therefore, the heightened prevalence of cardiovascular diseases is a primary driver behind the expansion of the cardiac biomarkers testing market.

Which Segment Categories Are Driving Maximum Growth In The Cardiac Biomarkers Testing Market?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

What Key Trends Are Driving Growth In The Cardiac Biomarkers Testing Market?

Leading companies in the cardiac biomarker testing market are forming strategic alliances to deliver technology that identifies early indicators of heart conditions and boosts patient outcomes. These collaborations within cardiac biomarker testing stimulate cooperation among firms, facilitating the creation of pioneering diagnostics, broadening market penetration, and quickening the introduction of sophisticated testing solutions to advance cardiovascular care. A notable example occurred in September 2024, when MediBuddy, an Indian healthcare technology company that offers an extensive platform for telehealth services, health management, and insurance support, collaborated with Philips, a Netherlands-based conglomerate corporation. Their objective with this collaboration is to elevate cardiac care in India through the integration of Philips’ HeartPrint technology, allowing for consistent monitoring and risk evaluation of heart health. This progressive strategy equips users with enhanced tools on the MediBuddy platform, thereby promoting a proactive stance on heart health management and achieving superior outcomes.

Who Are The Leading Companies Driving The Cardiac Biomarkers Testing Market?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

Which Region Holds The Largest Share In The Cardiac Biomarkers Testing Market Today?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

Browse Through More Reports Similar to the Global Cardiac Biomarkers Testing Market 2025, By The Business Research Company

Cardiovascular Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiac Assist Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiac Rhythm Management Crm Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-rhythm-management-crm-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795